bs-10202R [Primary Antibody]
HPV16 E7 Polyclonal Antibody
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: HPV16 E7

Immunogen Range: 11-70/98


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 1489079

Source: KLH conjugated synthetic peptide derived from HPV16 E7 protein

Purification: Purified by Protein A.

Storage Buffer: 0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.

Storage: Store at -20°C for 12 months.

Background:

Human papilloma viruses (HPVs) can be classified as either high risk or low risk according to their association with cancer. HPV16 and HPV18 are the most common of the high risk group while HPV6 and HPV11 are among the low risk types. Approximately 90% of cervical cancers contain HPV DNA of the high risk types. Mutational analysis have shown that the E6 and E7 genes of the high risk HPVs are necessary and sufficient for HPV transforming function. The specific interactions of the E6 and E7 proteins with p53 and pRB, respectively, correlate with HPV high and low risk classifications. The high risk HPV E7 proteins bind to pRB with a higher affinity than do the low risk HPV proteins, and only the high risk HPV E6 proteins form detectable complexes with p53 in vitro.

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IHC-P(1:200-400)
IF(IHC-P)(1:50-200)

Predicted Molecular Weight: 11


Cross Reactive Species: Virus
(HPV16)

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Siyang Zhang. et al. Nocardia rubra cell-wall skeleton influences the development of cervical carcinoma by promoting the antitumor effect of macrophages and dendritic cells. 2022 Jan 07Read more>>
  • Yahang Chen. et al. Human papillomavirus type 16 E7 promotes cell viability and migration in cervical cancer by regulating the miR-23a/HOXC8 axis. J OBSTET GYNAECOL. 2024 Feb 13Read more>>
VALIDATION IMAGES

Sample: hela (Human) Cell Lysate at 30 ug mcf-7 (Human) Cell Lysate at 30 ug mda-mb-231 (Human) Cell Lysate at 30 ug siha (Human) Cell Lysate at 30 ug recombinant HPV16-E7 protein (bs-49101P) 100 ng recombinant HPV16-E7 protein (bs-49101P) 50 ng Primary: Anti-HPV16 E7 (bs-10202R) at 1/1000 dilution Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution Predicted band size: 11 kD Observed band size: 17-20 kD bs-49101P band size: 45 kD


Lane 1: HPV16 E7 fusion protein (bs-49101P) 0.1ug Lysates; Lane 2: HPV16 E7 fusion protein (bs-49101P) 0.05ug Lysates. Probed with HPV16 E7 polyclonal Antibody, unconjugated (bs-10202R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.